CooperVision

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, CooperVision sits in the top decile of US sponsors by registered trial count (#323 of 15,742 sponsors by registered trial count).

64 total trials 2 currently recruiting 61 completed top decile by trial count

CooperVision: 64 sponsored US clinical trials, 2 recruiting.

CooperVision sponsors 64 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 61 completed. The most-studied condition in this pipeline is Myopia, with 13 trials.

Top-decile sponsor footprint

CooperVision ranks in the top decile of sponsors by registered trial count (#323 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

B 86/100

61 of 62 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (98.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Therapeutic Areas

What is open in the CooperVision pipeline

2 recruiting of 64 indexed (3% open); 61 completed (95%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Myopia (13 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

CooperVision: open-pipeline peers nationwide

Peers matched on 64 registered trials and 3% open enrollment, not the therapeutic-area sidebar.

CooperVision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 20406080100 0%10%20%30%40%50% Total trials Recruiting share CooperVisionCephalonNRG OncologyUniversity of HoustonWashington State UniversityAllina Health SystemMasimo CorporationMiMedx GroupSharp HealthCare
CooperVision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

CooperVision sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 64 trials (± recruiting share)

Sponsors near 3% open enrollment (± trial volume)

What to do with this CooperVision page

64 registered trials is a research-attention snapshot, not an endorsement of CooperVision or any single study.

  • 2 of CooperVision's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Myopia is the condition CooperVision studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myopia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

CooperVision pipeline card: 64 registered trials from official public datasets.Report a data error.